Schmiedl Sven, Szymanski Jacek, Rottenkolber Marietta, Drewelow Bernd, Haase Grit, Hippius Marion, Reimann Ilselore R, Siegmund Werner, May Karen, Haack Sara, Hasford Jörg, Thürmann Petra A
HELIOS Klinikum Wuppertal, Philipp Klee-Institut für Klinische Pharmakologie, Universität Witten/Herdecke, Witten/Herdecke.
Med Klin (Munich). 2007 Aug 15;102(8):603-11. doi: 10.1007/s00063-007-1064-x.
Although the value of digitalis glycosides in the treatment of heart failure is limited, approximately 255 million DDDs of digitalis glycosides (DGs) were prescribed in Germany in 2004.
The authors analyzed data from adverse drug reactions (ADRs) resulting in hospitalization in the four German Pharmacovigilance Centers (PVCs) associated with DGs between 2000 and 2004. All patients with an at least "probable" ADR were included.
Out of 3,092 ADR patients, in 314 patients (10.2%, 244 women) admission was caused by a DG-related ADR. Patients with DG-related ADR had a significantly lower body weight and were significantly older than patients with other ADRs. Per 1,000 patients exposed to DGs the incidence [95% CI] was calculated to 1.9 [1.0; 3.3] ADRs per 3 months exposition. Oral digitoxin was involved in 296 patients (228 women). 70.6% of women but only 29.3% of men were overdosed (> 1 mug/kg body weight per day). Women received significantly higher body weight-related digitoxin doses and had significantly higher digitoxin plasma levels than men. ADRs in patients with nonelevated digitoxin serum level were mainly caused by pharmacodynamic drug-drug interactions (e.g., beta-blockers). Overall, 42.4% of the ADRs were supposed to be preventable.
Body weight-adapted dosing of digitoxin is essential for preventing DG-ADRs, particularly in elderly women with low body weight. Beyond giving attention to pharmacodynamic and pharmakokinetic drug-drug interactions, regular measurements of digitoxin plasma concentrations are crucial accounting for the increased half-life of digitoxin in the very old.
尽管洋地黄糖苷在治疗心力衰竭方面的价值有限,但2004年德国开出了约2.55亿限定日剂量的洋地黄糖苷(DG)。
作者分析了2000年至2004年期间德国四个药物警戒中心(PVC)与DG相关的导致住院的药物不良反应(ADR)数据。纳入所有至少有“可能”ADR的患者。
在3092例ADR患者中,314例(10.2%,244例女性)因与DG相关的ADR入院。与DG相关的ADR患者体重明显较低,年龄明显大于其他ADR患者。每1000名接触DG的患者,每3个月暴露的发病率[95%置信区间]计算为1.9[1.0;3.3]例ADR。口服洋地黄毒苷涉及296例患者(228例女性)。70.6%的女性但只有29.3%的男性用药过量(>1微克/千克体重/天)。女性接受的与体重相关的洋地黄毒苷剂量明显高于男性,洋地黄毒苷血浆水平也明显高于男性。洋地黄毒苷血清水平未升高的患者发生的ADR主要由药效学药物相互作用(如β受体阻滞剂)引起。总体而言,42.4%的ADR被认为是可以预防的。
根据体重调整洋地黄毒苷的剂量对于预防DG-ADR至关重要,尤其是在体重较轻的老年女性中。除了关注药效学和药代动力学药物相互作用外,定期测量洋地黄毒苷血浆浓度对于考虑到洋地黄毒苷在高龄患者中半衰期延长至关重要。